Ivan Ovcharenko, Ph.D.

Senior Investigator

Ivan Ovcharenko's Research Group

NLM/NCBI

Building 38A, Room 6S602
8600 Rockville Pike
Bethesda, MD 20894

301-435-8944

ovcharen@nih.gov

Research Topics

The current research of the Ovcharenko group at NCBI focuses on deciphering the semantics and studying the evolution of the gene regulatory code in eukaryotes. The group uses comparative genomics, statistics, and machine learning to understand the DNA sequence encoding of tissue-specific regulatory elements and the links between regulatory element sequence variation and disease.

Biography

Dr. Ovcharenko is a tenure-track Investigator at the Computational Biology Branch of NCBI/NLM . He graduated from the Novosibirsk State University (Russia) with a PhD degree in Physics and Mathematics in 1999. Following his postdoctoral research at the UC Berkeley and Lawrence Berkeley National Laboratory (LBNL) centered on the development of computational methods for the identification of gene regulatory elements, Dr. Ovcharenko was leading evolutionary studies of gene regulatory mechanisms in vertebrate species as a tenure-track Scientist at the Lawrence Livermore National Laboratory (LLNL) and Joint Genome Institute (JGI).

Selected Publications

  1. Narlikar L, Sakabe NJ, Blanski AA, Arimura FE, Westlund JM, Nobrega MA, Ovcharenko I. Genome-wide discovery of human heart enhancers. Genome Res. 2010;20(3):381-92.

  2. Gotea V, Visel A, Westlund JM, Nobrega MA, Pennacchio LA, Ovcharenko I. Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Res. 2010;20(5):565-77.

  3. Taher L, McGaughey DM, Maragh S, Aneas I, Bessling SL, Miller W, Nobrega MA, McCallion AS, Ovcharenko I. Genome-wide identification of conserved regulatory function in diverged sequences. Genome Res. 2011;21(7):1139-49.

  4. Pennacchio LA, Loots GG, Nobrega MA, Ovcharenko I. Predicting tissue-specific enhancers in the human genome. Genome Res. 2007;17(2):201-11.

  5. Li S, Ovcharenko I. Human Enhancers Are Fragile and Prone to Deactivating Mutations. Mol Biol Evol. 2015;32(8):2161-80.


This page was last updated on May 10th, 2013